Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | AXL over exp BRAF V600E |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| AXL over exp BRAF V600E | melanoma | sensitive | Bemcentinib + Vemurafenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Bemcentinib (BGB-324) and Zelboraf (vemurafenib) combination treatment synergistically inhibited viability of melanoma cell lines harboring BRAF V600E and overexpressing Axl in culture, and resulted in improved tumor growth inhibition and tumor regression over either agent alone in a cell line xenograft model (PMID: 35332208). | 35332208 |